• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advanced Functional Materials >Self-Assembled/Drug-Composed Nanomedicine for Synergistic Photonic Hyperthermia and Targeted Therapy of Breast Cancer by Inhibiting ERK, AKT, and STAT3 Signaling Cascades
【24h】

Self-Assembled/Drug-Composed Nanomedicine for Synergistic Photonic Hyperthermia and Targeted Therapy of Breast Cancer by Inhibiting ERK, AKT, and STAT3 Signaling Cascades

机译：自组装/药物组成的纳米药物，通过抑制ERK，AKT和STAT3信号传导级联，用于协同光子热疗和乳腺癌的靶向治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Superior to chemotherapy, photonic hyperthermia and targeted therapy have made attractive impacts on cancer treatment by virtue of their profound advantages such as high specificity and minimal invasiveness, but the rational integration of corresponding therapeutic drugs for achieving concurrent photothermal ablation/targeted therapy is still challenging. Herein, a self-assembled nanomedicine Anlotinib@IR820 is constructed with drug formulations for highly efficient and synergistic photonic hyperthermia and targeted therapy against breast cancer. Specifically, the constructed Anlotinib@IR820 nanomedicine presents high accumulation at the tumor site owing to the enhanced permeability and retention effect and simultaneously overcomes the obstacles of poor water solubility of Anlotinib (for targeted therapy) and the short lifetime of IR820 (for photonic ablation). The photothermal ablation as activated by near-infrared laser can not only irradiate cancer cells but also promote the cellular uptake of Anlotinib, which presents a profound synergistic function both in vitro and in vivo. Mechanically, Anlotinib@IR820 nanomedicine can induce apoptosis and cause cell cycle arrest in breast cancer through inhibiting ERK, AKT, and STAT3 pathways. Therefore, the rationally designed drug-composed Anlotinib@IR820 nanomedicine exhibits high clinical translation potential because of its therapeutic nanoformulation, which provides an alternative option for efficient combinational therapy of breast cancer.
机译：光化学热疗和靶向疗法优于化学疗法，凭借其高特异性和微创性等深远优势对癌症治疗产生了诱人的影响，但是合理整合相应的治疗药物以实现同时的光热消融/靶向疗法仍然具有挑战性。在此，用药物制剂构建了自组装的纳米药物Anlotinib @ IR820，用于高效和协同的光子热疗和针对乳腺癌的靶向治疗。具体而言，构建的Anlotinib @ IR820纳米药物由于增强的通透性和保留效果而在肿瘤部位呈现高积累，同时克服了Anlotinib水溶性差（用于靶向治疗）和IR820寿命短（用于光子消融）的障碍。 。由近红外激光激活的光热消融不仅可以照射癌细胞，而且可以促进Anlotinib的细胞摄取，从而在体内和体外均表现出深远的协同作用。从机械上讲，Anlotinib @ IR820纳米药物可通过抑制ERK，AKT和STAT3途径诱导凋亡并导致乳腺癌细胞周期停滞。因此，合理设计的药物组成的Anlotinib @ IR820纳米药物由于其治疗性纳米制剂而具有很高的临床翻译潜力，为​​乳腺癌的有效联合治疗提供了另一种选择。

著录项

  • 来源
    《Advanced Functional Materials》 |2020年第10期|1908907.1-1908907.13|共13页
  • 作者

  • 作者单位

    Shanghai Jiao Tong Univ Shanghai Key Lab Orthoped Implants Dept Orthoped Surg Shanghai Peoples Hosp 9 Sch Med Shanghai 200011 Peoples R China;

    Chinese Acad Sci State Key Lab High Performance Ceram & Superfine Shanghai Inst Ceram Shanghai 200050 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Anlotinib; breast cancer; IR820; photothermal therapy; targeted therapy;

    机译：安洛替尼;乳腺癌;IR820;光热疗法靶向治疗;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号